Genentech Stops Avastin Ovarian Cancer Trial Enrollment After GI Perforations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech is discontinuing enrollment of a Phase II study of Avastin (bevacizumab) in platinum-refractory ovarian cancer patients due to an excessively high rate of reported gastrointestinal perforations
You may also be interested in...
Cytokinetics Ispinesib Could Help Fill Gap In HER2 Negative Breast Cancer
Cytokinetics is casting a wider net with its development program for ispinesib following the targeted oncologic’s failure earlier this year in a Phase II lung cancer trial.
Avastin lung cancer sBLA
Genentech is requesting priority review of an sBLA supporting a first-line non-small cell lung cancer claim for Avastin (bevacizumab). The new claim, submitted April 10, is based on an 878-patient trial that showed a 25% improvement in overall survival for patients on Avastin plus paclitaxel and carboplatin versus chemotherapy alone. Another sBLA in metastatic breast cancer is slated for submission during the second quarter. In October, Genentech discontinued an Avastin trial in ovarian cancer following reports of high gastrointestinal perforation rates (1Pharmaceutical Approvals Monthly October 2005, p. 14)...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011